Millennium Biotechnologies, Inc. Announces The Completion Of It’s Clinical Study Of Athletes Using Resurgex(R)

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Nov. 16, 2005-- Final results of a clinical trial finds significant reduced oxidative stress markers and longer time to exhaustion in Rutgers’ University soccer players using Resurgex(R). Millennium Biotechnologies, Inc., (OTCBB:MBTG), a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements for the medical market, today announced the final results of a double blind, placebo controlled clinical trial that found its Resurgex(R) nutritional formula provided enhanced performance and reduced oxidative stress levels (free radical damage caused by exercise) in Rutgers University Division 1 soccer players. Oxidative stress in the body is caused by an imbalance or overload of oxidants (free radicals from air, food, metabolism, medications, stress, disease, etc.) which can have devastating effects on health and disease states. Sustained oxidative stress contributes to increased susceptibility to injury and reduced performance in athletes. On the clinical side, oxidative stress is involved in the cause of many chronic degenerative diseases as seen in immunocompromised conditions such as Cancer and AIDS. This new data confirms an important role for Resurgex in the sports fitness field in addition to its already proven benefits for immunocompromised patients.

MORE ON THIS TOPIC